XVIVO Q2 2025 slides reveal -11% organic growth amid market headwinds

XVIVO Perfusion AB reported a significant Q2 2025 downturn, with net sales down 15% and organic growth falling 11% year-over-year, primarily driven by market headwinds in its core US thoracic (lung transplant) segment, which also impacted adjusted EBITDA. Despite these results, the stock rose 3.39% on the day, supported by strong 19% organic growth in the abdominal segment and promising clinical advancements, including positive heart trial results targeting Q3 2025 commercial launch and FDA Breakthrough Designation for Liver Assist. The mixed performance indicates current market challenges but highlights future growth potential from its pipeline and long-term market demand, contingent on recovery in the core thoracic business.

Analysis

XVIVO Perfusion AB (STO:XVIVO) reported a significant operational downturn in its Q2 2025 results, with a 15% total decline in net sales to SEK 178 million and a negative 11% organic growth rate, a stark reversal from the 14% organic growth in Q1. The primary driver of this weakness was the core Thoracic segment, which contracted 19% organically due to headwinds in the US lung transplant market, including public funding cuts, a slowdown in EVLP procedures, and destocking by a major customer. This performance drop severely impacted profitability, with the adjusted EBITDA margin compressing to 13% from 24% in the prior-year period, and operating cash flow declining to SEK 9 million from SEK 25 million. Despite these figures, the stock reacted positively, rising 3.39%, indicating investors are looking beyond the immediate challenges. This optimism is likely fueled by two key factors: the strong performance of the Abdominal segment, which grew 19% organically, and significant progress in the company's clinical pipeline. XVIVO presented compelling 12-month follow-up data for its heart trial, showing a 76% risk reduction in severe PGD, and is targeting a European commercial launch in Q3 2025. Furthermore, its liver technology received FDA Breakthrough Device Designation, with a pivotal US trial set to begin in Q3 2025. This creates a clear dichotomy between near-term operational struggles in a core market and high-potential, de-risked pipeline assets nearing commercialization.

Key Decisions for Investors

• Investors should weigh the significant Q2 operational miss and weakened cash flow against the strong, near-term clinical pipeline catalysts in the heart and liver segments, which the market appears to be prioritizing.
• Closely monitor the performance of the core Thoracic segment in subsequent quarters for signs of stabilization in the US market, as a recovery in EVLP uptake is critical for restoring overall profitability and validating the near-term business model.
• The targeted Q3 2025 European launch of Heart Assist Transport and the initiation of the US DeLIVER trial for the liver product are key inflection points that could significantly re-rate the stock, irrespective of immediate thoracic segment performance.